<DOC>
	<DOCNO>NCT02140151</DOCNO>
	<brief_summary>This study determine whether quarterly injection Ranibizumab may prevent eye dry age-related macular degeneration progress wet age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Prophylactic Ranibizumab Exudative Age-related Macular Degeneration</brief_title>
	<detailed_description>This multicenter , prospectively randomize , mask control , interventional investigator sponsor phase I/II study subject high-risk nonexudative age-related macular degeneration ( AMD ) treat intravitreal ranibizumab quarterly prophylaxis conversion exudative age-related macular degeneration . The objective study investigate safety efficacy prophylactic anti-vascular endothelial growth factor ( VEGF ) therapy ranibizumab prevent development exudative AMD eye high-risk nonexudative AMD . In addition , baseline characteristic high-risk eye ( fundus feature , optical coherence tomography ( OCT ) parameter genetic profile ) evaluate determine predictive value conversion exudative AMD . The effect ranibizumab atrophic component AMD also monitor .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Adult 50 year old Able sign inform consent comply study protocol duration two year Nonexudative agerelated macular degeneration ( AMD ) one eye ( study eye ) History exudative AMD one eye ( fellow eye ) diagnose within 5 year study enrollment Participation another simultaneous medical investigation clinical trial Patient pregnant , lactating , premenopausal use adequate contraception Known serious allergy ranibizumab , fluorescein dye , drug pupillary dilation , topical anesthetic , sterilize solution ( e.g . Betadine solution ) Presence ocular condition increase risk choroidal neovascularization ( CNVM ) pigment epithelial detachment ( PED ) , include presume ocular histoplasmosis syndrome ( POHS ) , traumatic choroidal rupture , angioid streak , pathologic myopia ( spherical equivalent ≥ 8 diopter axial length ≥ 25 mm ) , multifocal choroiditis , macular choroidal nevus , polypoidal choroidal vasculopathy ( PCV ) , idiopathic central serous chorioretinopathy ( ICSC ) , etc . History vitrectomy study eye History cataract surgery within 3 month enrollment History yttrium aluminum garnet ( YAG ) capsulotomy within 1 month enrollment History intraocular periocular corticosteroid therapy within past 90 day History therapeutic radiation region study eye . Presence medium opacity would preclude adequate examination and/or image Concurrent macular condition would affect study parameter ( epiretinal membrane , macular hole , macular edema ) require treatment within duration study Any progressive ocular condition ( uncontrolled glaucoma , diabetic retinopathy , uveitis ) may affect visual acuity duration study Active ocular infection ( i.e. , bacterial , viral , parasitic , fungal ) either eye enrollment Presence advance systemic condition may hinder patient participation completion study Concurrent use systemic antiVEGF therapy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>amd</keyword>
	<keyword>non-exudative macular degeneration</keyword>
	<keyword>exudative macular degeneration</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>anti-VEGF</keyword>
</DOC>